Lung Cancer
Volume 69, Issue 3 , Pages 259-264 , September 2010

Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer

  • Eckart Laack

      Affiliations

    • Ambulantes Krebszentrum Hamburg, Hamburg, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 40 889009860; fax: +49 40 889009866.
    • ,
  • Guido Sauter

      Affiliations

    • Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Carsten Bokemeyer

      Affiliations

    • Department of Oncology, Hematology, and BMT with section Pneumology, Hubertus-Wald-Tumorzentrum, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Received 19 December 2009 ,Revised 7 May 2010 ,Accepted 13 May 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0169-5002(10)00230-8

doi: 10.1016/j.lungcan.2010.05.015

Lung Cancer
Volume 69, Issue 3 , Pages 259-264 , September 2010

Article Tools

* Image Usage & Resolution